# Insulet Corporation – Consensus ‘buy’ rating and 35.2% Upside Potential

- Link: https://www.directorstalkinterviews.com/insulet-corporation-consensus-buy-rating-and-35.2-upside-potential/4121151871
- Published: 2024-04-16T12:11:41+01:00
- Author: Charlotte Edwards

**Insulet Corporation** which can be found using ticker (PODD) have now 18 confirmed
analysts covering the stock with the consensus suggesting a rating of ‘buy’. The
range between the high target price and low target price is between $270.00 and 
$208.00 suggesting an average Analsyt target price of $236.83. Given that the stocks
previous close was at $175.22 this indicates there is a potential upside of 35.2%.
The day 50 moving average is $176.83 and the 200 moving average now moves to $193.74.
The market capitalization for the company is 12.18B. The stock price for the company
is currently is currently $173.94 USD

 The potential market cap would be $16,462,284,188 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 59.16, revenue per share of $24.33
and a 6.09% return on assets.

Insulet Corporation is primarily engaged in the development, manufacture and sale
of its Omnipod System, a continuous insulin delivery system for people with insulin-
dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System(
Classic Omnipod), the Omnipod DASH Insulin Management System (Omnipod DASH), and
the Omnipod 5 Automated Insulin Delivery System (Omnipod 5). The Omnipod System 
features a small, lightweight, self-adhesive disposable tubeless Omnipod device (
Pod) that the user fills with insulin and wears directly on the body for up to three
days at a time, which delivers personalized doses of insulin, and the Personal Diabetes
Manager (PDM) or Controller, a wireless, handheld device that programs the Pod with
the user’s personalized insulin-delivery instructions and wirelessly monitors the
Pod’s operation. The Company sells Pods to Amgen Inc. (Amgen) for use in the Neulasta
Onpro kit, a delivery system for Amgen’s Neulasta.

Share on: